NMTCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30

NEUROONE MEDICAL TECHNOLOGIES Corp

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.00+0.04 (+4.01%)

Close on Oct 19, 2026

Market cap: $8.74M
P/E (TTM): –
Dividend yield: –

NEUROONE MEDICAL TECHNOLOGIES Corp income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	9.10	3.45	1.95	0.17	0.18	–	–	0	0	0.00	0.00	0.00	0.01	0.00
Cost of Revenue	3.96	2.37	1.50	0.24	0.28	–	–	–	–	–	–	0	0.00	–
Gross Profit	5.14	1.08	0.46	-0.07	-0.10	–	–	–	–	–	0.00	0.00	0.00	0.00
Research & Development	4.98	5.07	6.94	4.93	3.93	2.08	0.74	–	–	–	–	–	–	–
Selling, General & Admin	7.38	7.90	6.93	6.98	6.26	–	–	–	–	–	–	–	–	–
General & Administrative	5.85	6.50	–	–	6.26	4.75	2.34	0.03	0.03	0.04	0.03	0.00	0.03	0.01
Advertising Expenses	0.17	0.11	0.17	0.27	0.34	–	–	0	0	0	–	–	–	–
Operating Expenses	12	13	14	12	10	6.83	3.07	0.03	0.03	0.04	0.03	0.01	0.03	0.01
Operating Income	-4.23	-12	-12	-10	-10	-4.90	-3.07	-0.03	-0.03	-0.04	-0.03	-0.01	–	–
Interest Expense	–	–	–	–	0.00	–	0.04	–	0.01	0.00	–	0.00	0.00	–
Other Non-Operating Income	–	0.13	0.10	0.03	–	–	–	–	–	0.00	-0.01	0.00	–	–
Gain (Loss) on Sale of Assets	–	–	-0.03	–	0.05	0.02	–	–	–	–	–	–	–	–
Pretax Income	-3.61	-12	-12	-10.00	–	-2.02	–	-0.03	-0.03	-0.04	-0.03	-0.01	–	–
Income Tax Expense	–	–	–	–	-0.27	–	–	0	0	0	–	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	-0.03	-0.03	0	–	-0.01	-0.03	-0.01
Income from Discontinued Operations	–	–	–	–	–	–	–	-0.02	-0.02	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-9.95	-14	–	–	–	–	–	-0.01	-0.03	-0.01
Net Income	-3.61	-12	-12	-10.00	-9.95	-14	-5.06	-0.05	-0.06	-0.04	-0.03	-0.01	-0.03	-0.01
EPS (Basic)(per share)	-0.54	-2.76	-3.90	-3.78	-5.58	-15.12	-13.86	-0.18	-0.18	-0.18	-0.18	0.00	-0.18	–
EPS (Diluted)(per share)	-0.54	-2.76	-3.90	-3.78	-5.58	-15.12	-13.86	-0.18	-0.18	-0.18	-0.18	0.00	-0.18	–
Shares Outstanding (Basic, Weighted)(shares)	6.69	4.46	3.02	2.67	1.78	0.90	0.37	0.28	0.28	0.28	0.28	0.28	0.26	0.24
Shares Outstanding (Diluted, Weighted)(shares)	6.69	4.46	3.02	2.67	1.78	0.90	0.37	0.28	0.28	0.28	0.28	0.28	0.26	0.24
EBITDA	-3.96	-12	-12	-9.91	-10	-4.85	–	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	0.00	-7.52	-1.40	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 55.6%
Operating margin: -83.4%
Net margin: -78.6%
Return on equity, FY2025: -91.3%

Financial strength

Current ratio: 2.84
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 100.3%

Valuation

P/E ratio: –
Price to sales: 0.92
Price to book: 2.32
Dividend yield: –